~~<i id='BC1D907765'><strike id='BC1D907765'><tt id='BC1D907765'><pre id='BC1D907765'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：fashion 2025-09-02 08:13:27 - browse：99946

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

leisure time

focus

entertainment

hotspot

leisure time

focus

APStockBlackpatientsaresystematicallyundertreatedforpain,decadesofresearchhaveshown.Andastudypublish

WSS

SCOTUS to consider access to abortion pill mifepristone

Bird flu makes raw milk dangerous to consume, mouse study finds

Patients' immediate access to test results puts radiologists in a bind

Unmasking the 'centricity' illusion in clinical trials

Louisiana bill approved classifying abortion pills as controlled substances

Clinicians often fail to acknowledge the pain caused by long Covid

focus

explore

leisure time

Drug repurposing or repositioning? The language matters

Americans' trust in science, scientist continues decline: Report

Medicare proposal to cover medical devices draws a mixed reaction

After sickle

After affirmative action ruling, medical educators look to 'holistic review'

Patients' immediate access to test results puts radiologists in a bind

The cancer drug shortage isn’t new — and neither are the solutions

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The world needs the new pandemic treaty

focus

What PEPFAR has meant on the ground in Ukraine

Should insurance cover cosmetic surgery?

Should insurance cover cosmetic surgery?

Congenital heart disease patients face new threat of heart failure

Pharma patents targeted by Biden in move to slash drug prices

Pfizer plans to depart BIO

entertainment

hotspot

leisure time

focus